Q4 2022 13F Holders as of 12/31/2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
77.3M
-
Number of holders
-
155
-
Total 13F shares, excl. options
-
60.4M
-
Shares change
-
+949K
-
Total reported value, excl. options
-
$2.38B
-
Value change
-
+$39.3M
-
Put/Call ratio
-
0.16
-
Number of buys
-
79
-
Number of sells
-
-60
-
Price
-
$39.43
Significant Holders of Xenon Pharmaceuticals Inc. - Common Stock (XENE) as of Q4 2022
180 filings reported holding XENE - Xenon Pharmaceuticals Inc. - Common Stock as of Q4 2022.
Xenon Pharmaceuticals Inc. - Common Stock (XENE) has 155 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 60.4M shares
of 77.3M outstanding shares and own 78.06% of the company stock.
Largest 10 shareholders include Avoro Capital Advisors LLC (4.9M shares), FMR LLC (4.69M shares), DRIEHAUS CAPITAL MANAGEMENT LLC (4.68M shares), Polar Capital Holdings Plc (3.05M shares), MARSHALL WACE, LLP (2.37M shares), Redmile Group, LLC (2.36M shares), Capital World Investors (2.27M shares), LORD, ABBETT & CO. LLC (2.12M shares), PICTET ASSET MANAGEMENT SA (2.12M shares), and Capital International Investors (2.1M shares).
This table shows the top 155 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.